Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 17,648

Document Document Title
WO/2019/007866A1
The invention relates to a composition comprising an electron-transporting host and a hole transporting host, to the use thereof in electronic devices and electronic devices containing said composition. The electron-transporting host is ...  
WO/2019/009412A1
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...  
WO/2019/010014A1
The present disclosure teaches the use of a dual-acting opioid agonist for the treatment of pain (e.g., inflammatory pain). The opioid agonist activates both the kappa and delta opioid receptors to provide synergistic reduction in pain. ...  
WO/2019/009249A1
The present invention provides a photoelectric conversion element that has a photoelectric conversion film having excellent suitability for vapor deposition and that exhibits excellent photoelectric conversion efficiency even in a case w...  
WO/2019/003148A1
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. F...  
WO/2019/000494A1
Provided is a fluorene-based organic electroluminescent compound, having the following structure: The compound has good thermal stability, high luminous efficiency, and high luminous purity, and can be used for manufacturing organic elec...  
WO/2019/006002A1
The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are methods and kits for treating cance...  
WO/2019/004614A1
The present invention provides a novel heterocyclic compound and an organic light emitting element using same.  
WO/2019/001420A1
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2018/234926A1
A novel organic compound is provided. That is, a novel organic compound that is effective in improving the element characteristics and reliability is provided. The organic compound has a benzofuropyrimidine skeleton or a benzothienopyrim...  
WO/2018/234805A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.  
WO/2018/234343A1
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/235838A1
The purpose of the present invention is to provide a compound that can be useful for prevention of, or therapy for, constipation and the like. The present invention provides: a compound represented by formula (I) (refer to the descriptio...  
WO/2018/234932A1
A novel compound is provided. A light-emitting element with high emission efficiency and a long lifetime is provided. The compound is an organic compound that includes a benzofuro[3,2-d]pyrimidine or benzothieno[3,2-d]pyrimidine skeleton...  
WO/2018/234917A1
Provided is a novel organic compound. In particular, provided is a novel organic compound capable of improving element characteristics of a light-emitting element. Further provided is a novel light-emitting element having excellent light...  
WO/2018/234284A1
The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2018/235926A1
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...  
WO/2018/229079A1
A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inf...  
WO/2018/229717A1
The present invention provides compositions comprising loline alkaloids including pesticidal compositions, methods of producing the compositions and uses of the compositions including uses as control agents. Methods for the control of pe...  
WO/2018/229511A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic and M4 receptors. Also provided are pharmaceutical compositions co...  
WO/2018/229665A1
The present invention relates to novel spirobibenzopyran conjugate derivatives with potent anti- cancer activity as pharmaceutical agents, their stereoisomers, their polymorphs and their pharmaceutically acceptable salts and their pharma...  
WO/2018/226155A1
The present invention relates to compounds of Formula I, wherein A, R1 to R6, and x to z are defined herein, and their use in inhibiting Human trefoil factor 3.  
WO/2018/227058A1
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...  
WO/2018/226769A1
Compounds of Formula (I) that antagonize vasopressin receptors, particularly the Via receptor. The compounds are useful for treating e.g. neuropsychological disorders, such as e.g. anxiety, depression and schizophrenia. Preferred compoun...  
WO/2018/221433A1
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...  
WO/2018/215318A1
The invention relates to heteroaromatic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices containing same.  
WO/2018/215800A1
The present invention relates to certain compounds that function as inhibitors of bacterial metallo-beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions c...  
WO/2018/216822A1
Provided are novel compounds represented by the following general formula [1] or pharmaceutically acceptable salts thereof, that inhibit LpxC, as well as pharmaceutical drugs comprising those compounds or pharmaceutically acceptable salt...  
WO/2018/210729A1
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...  
WO/2018/212774A1
The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras ...  
WO/2018/212216A1
Provided is a method for producing an optically active isomer, the method including an asymmetry induction step in which an asymmetry-inducing agent is caused to act on chiral molecules having an enantiomeric-excess half-life period less...  
WO/2018/210229A1
Disclosed are a series of α-7 nicotine acetylcholine receptor agonists, and specifically disclosed are compounds of formula (I), pharmaceutically acceptable salts thereof or tautomers thereof, and pharmaceutical uses thereof.  
WO/2018/213807A1
Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject...  
WO/2018/207729A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has the potential to be used as a therapeutic agent for essential tremor, small fiber neuropathy, dystonia, epilepsy associated with Alzheimer's disease,...  
WO/2018/207715A1
Provided are crystals of a compound represented by formula (I) that are available as an active pharmaceutical ingredient of medicinal products.  
WO/2018/208127A1
The present invention provides a novel-structured heterocyclic compound and an organic light emitting element comprising the same.  
WO/2018/206590A1
The invention provides a novel class of natural azaphilone pigments, called atrorosins, and methods for their production. The methods for the production of atrorosins include production by fermentation using a fungal species belonging to...  
WO/2018/203298A1
The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceuti...  
WO/2018/200855A1
The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, an...  
WO/2018/195321A1
Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.  
WO/2018/192864A1
The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.  
WO/2018/188495A1
The present invention relates to a preparation method for a compound of Mod.I crystal form of 4-(4-chloroanilino)-7-(2-methylaminocarbonyl-4-oxomethyl)pyr idylfuro[2,3-d]pyridazine methanesulfonate (EOC315), crystal form characterization...  
WO/2018/187295A1
Near infrared and shortwave infrared dyes can have polymethine structures.  
WO/2018/177981A1
The invention relates to aromatic compounds which are suitable for synthesizing asymmetrical polydentate ligands. The invention further relates to a method for synthesizing asymmetrical polydentate ligands and metal complexes comprising ...  
WO/2018/176350A1
Disclosed in the present invention is a synthesis method for a spiro hydroxyindole cyclopentane β-intra-ester compound. Specifically, reactions are carried out by using phenyl-unsaturated aldehyde and unsaturated keto ester as reactants...  
WO/2018/181777A1
Provided is a compound which has tyrosine kinase inhibitory activity specific against C797S mutation-type resistant EGFR (particularly, C797S mutation-type tertiary resistant EGFR), and is useful as a C797S mutation-type resistant EGFR (...  
WO/2018/183964A1
Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1 -dependent disorders and enhancing an immune response. Also described are methods of inhibiting ...  
WO/2018/182050A1
Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I) : wherein each symbol is as described in the DESCRIPTION, or a salt thereof may...  
WO/2018/178556A1
The invention relates to a crosslinking compound of formula (I). In particular, the present invention relates to a liquid composition comprising a monomer, a (meth)acrylic polymer and at least one crosslinking compound of formula (I). Th...  
WO/2018/182300A1
The present specification relates to a heterocyclic compound of chemical formula 1 and an organic light-emitting device comprising same.  

Matches 1 - 50 out of 17,648